Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16168059 | 1.00 | NR1I2 (0.49) | NR1I2GAAKMT2AHSD17B3HDAC8 | |
| SCHEMBL12172229 | 0.97 | NR1I2 (0.47) | NR1I2GAAKMT2AHSD17B3HDAC8 | |
| SCHEMBL18800441 | 0.97 | NR1I2 (0.47) | NR1I2GAAKMT2AHSD17B3HDAC8 | |
| SCHEMBL12337676 | 0.93 | NR1I2 (0.57) | NR1I2GAAKMT2AHSD17B3HDAC8 | |
| SCHEMBL25334303 | 0.88 | NR1I2 (0.43) | NR1I2GAAKMT2AHSD17B3HDAC8 | |
| SCHEMBL11739471 | 0.86 | S1PR2 (0.47) | GAAGPR84 | |
| SCHEMBL10955282 | 0.86 | TP53 (0.54) | NR1I2KMT2ATP53TSHR | |
| SCHEMBL10956897 | 0.86 | TP53 (0.54) | NR1I2KMT2ATP53TSHR | |
| SCHEMBL10960609 | 0.86 | TP53 (0.54) | NR1I2KMT2ATP53TSHR | |
| SCHEMBL10957775 | 0.86 | TP53 (0.54) | NR1I2KMT2ATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NR1I2 4794/4885GAA 2685/4885KMT2A 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.